Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma

被引:14
|
作者
Wehle, MJ
Lisson, SW
Buskirk, SJ
Broderick, GA
Young, PR
Igel, TC
机构
[1] Mayo Clin, Coll Med, Dept Urol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Coll Med, Dept Radiat Oncol, Jacksonville, FL 32224 USA
关键词
D O I
10.4065/79.3.314
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate whether preoperative genitourinary variables in patients undergoing brachytherapy for localized prostate adenocarcinoma could predict postoperative genitourinary tract morbidity. Patients and Methods: We retrospectively reviewed medical records of 105 men who received either iodine 125. or palladium 103 radioactive seed implants with or without external beam radiotherapy or hormone blockade from January 1, 1998, through December 31, 2000, at the Mayo Clinic in Jacksonville, Fla. Patients with one or more of the following were classified as having a high risk of postoperative genitourinary tract morbidity: American Urological Association symptom scores greater than 15, maximum urinary flow rate less than 10 mL/s, postvoid residual urinary volume greater than 100 mL, or prostate volume greater than 40 cm(3). Of the 105 men, 59 (56%) were classified as high risk and 46 (44%) as low risk. Mean follow-up after brachytherapy was 23.6 months. Modified Radiation Therapy Oncology Group scores were used to assess postoperative genitourinary tract morbidity. The term significant genitourinary tract morbidity was applied to patients with a Radiation Therapy Oncology Group grade of 3 or 4 after at least 6 months of follow-up. Results: Significant morbidity occurred in 37% of high-risk vs 15% of low-risk patients (P=.006). In high-risk patients, transurethral resection or incision of the prostate was required in 5 patients, urethral dilation in 4, direct-vision internal urethrotomy in 1, and placement of a suprapubic catheter in 1. In low-risk patients, transurethral incision of the prostate was required in only 1 patient. Urinary flow rate was a significant individual predictor of postoperative morbidity (P=.03). Conclusions: A combination of urinary flow rate, prostate volume, postvoid residual urinary volume, and American Urological Association symptom score can help identify patients with underlying voiding dysfunction. Urinary flow rate was a statistically significant predictor of genitourinary tract morbidity after brachytherapy for localized prostate adenocarcinoma. Patients and physicians should consider these factors before a patient decides to undergo brachytherapy.
引用
收藏
页码:314 / 317
页数:4
相关论文
共 50 条
  • [1] Morbidity after brachytherapy for prostate adenocarcinoma
    Crook, J
    MAYO CLINIC PROCEEDINGS, 2004, 79 (07) : 945 - 945
  • [2] Morbidity after brachytherapy for prostate adenocarcinoma - In reply
    Blute, ML
    Frank, I
    MAYO CLINIC PROCEEDINGS, 2004, 79 (07) : 948 - 949
  • [3] Lower urinary tract morbidity after prostate brachytherapy with cesium-131
    Smith, R.
    Beriwal, S.
    Vargo, J.
    Benoit, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [4] American brachytherapy society recommendations for reporting morbidity after prostate brachytherapy
    Nag, S
    Ellis, RJ
    Merrick, GS
    Bahnson, R
    Wallner, K
    Stock, R
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (02): : 462 - 470
  • [5] The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy
    Niehaus, A
    Merrick, GS
    Butler, WM
    Wallner, KE
    Allen, ZA
    Galbreath, RW
    Adamovich, E
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01): : 136 - 143
  • [6] GENITOURINARY TOXICITY IN PROSTATE HDR BRACHYTHERAPY
    Aleknavicius, E.
    Burneckis, A.
    Ivanauskas, A.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S381 - S382
  • [7] Devastating complications after brachytherapy in the treatment of prostate adenocarcinoma
    Moreira, SG
    Seigne, JD
    Ordorica, RC
    Marcet, J
    Pow-Sang, JM
    Lockhart, JL
    BJU INTERNATIONAL, 2004, 93 (01) : 31 - 35
  • [8] POSTIMPLANT DOSIMETRY AND URINARY MORBIDITY AFTER PERMANENT PROSTATE BRACHYTHERAPY
    Schaefer, J.
    Wetzel, G.
    Wenz, F.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S336 - S336
  • [9] Urinary morbidity after 125I brachytherapy of the prostate
    Mallick, S
    Azzouzi, R
    Cormier, L
    Peiffert, D
    Mangin, P
    BJU INTERNATIONAL, 2003, 92 (06) : 555 - 558
  • [10] Decrease of acute urinary morbidity with experience after prostate brachytherapy
    Le Fur, E.
    Malhaire, J. -P
    Valeri, A.
    Rousseau, B.
    Baverez, D.
    Fournier, G.
    Pradier, O.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 59 - 60